The profitable effects of bisphosphontes on treatment of osteoporosis have been consistently reported in Japan as in the United States and European countries. Alendronate and risedronate increased bone mineral density and reduced the risk of vertebral fracture. Histomorphomeric analysis and microCT have confirmed that normal bone microarchitecture and mineralization are preserved after 3 or 5 years of treatment. Long-term (7 or 10 years) treatment with bisphosphonates seemed to have a sustained effect on BMD and bone turnover, however, the optimal duration of bisphosphonate treatment is unresolved.